CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Vancomycin +1 moredrug
Likely dose
Vancomycin 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03452189
NCT03452189Phase 2Completed

The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome

NYU Langone Health·interventional·Posted Mar 2, 2018·Updated Mar 26, 2021

In Brief

A Phase 2 clinical trial evaluating Vancomycin and Placebo for End Stage Renal Disease. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if multiple doses of vancomycin over the course of 3 months will perturb the intestinal flora (microbiome) and result in reduced serum concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the study will permit investigators to assess the variability of serum uremic retention solute concentrations with and without antibiotic over a three-month period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 2, 2018
Enrollment StartNov 27, 2017
Primary CompletionAug 18, 2018
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.3 years ago

Interventions

Vancomycindrug

Oral vancomycin 250mg capsules

Placeboother

Placebo Pills distributed by Research Pharmacy labeled "placebo."